Agreement - May 27, 2019
Affibody in agreement with 3P Biopharmaceuticals
The agreement with 3P Biopharmaceuticals (3P) covers process development and GMP manufacturing of Affibody’s ABY-035 drug. “Ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise”, said David Bejker, CEO of Affibody. “The work […]
Agreement - May 14, 2019
TATAA signs distribution agreement with SensID
In the agreement, SensID gives TATAA full access to its growing product portfolio for molecular diagnostics and TATAA will represent SensID in Sweden, Denmark, Norway, Finland, Czech and Slovak Republics. “With its strong focus on reference materials for molecular diagnostics, SensID is a perfect solution provider for our services. The SenseID products are also most attractive to our […]
Agreement - April 10, 2019
LEO Pharma and Elektrofi expand their partnership
The two companies have announced an expansion of their partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology. As part of the agreement LEO Pharma and Elektrofi will initially co-develop two specific antibodies. The agreement includes an option to a […]
Agreement - April 10, 2019
Genovis collaborates with Thermo Fisher Scientific
The two companies have entered into a collaboration agreement to develop advanced end-to-end workflows for the preparation, characterization and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS). The collaborative partnership aims to develop advanced end-to-end methods for the analysis of novel and complex biotherapeutics to meet the increasing demands for high throughput, […]
Agreement - March 20, 2019
Affibody announces co-development agreement with Alexion
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody with an upfront payment of $25 million, with the potential for additional development- and sales-based milestones of up to $625 million and tiered low double-digit […]
Agreement - February 25, 2019
Novo Nordisk and Abbott enter partnership
The two companies have announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system). The partnership reflects both companies’ commitment to make diabetes management easier by connecting key […]
